COMPANY
TNF Pharmaceuticals
Timeline
- Raise Private placement: $7M (total, as published), announced Sep 4, 2025. Source: SEC filing. source ↗
- Trial start Phase 2: Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures source ↗
- Trial start Phase 2: Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty source ↗
- Trial start Phase 1: Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects source ↗
- Trial start Phase 1: Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects source ↗
Funding
- Private placement: $7M (total, as published), announced Sep 4, 2025. Source: SEC filing. source ↗
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06942182 | Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures | Phase 2 | Not yet recruiting | May 1, 2025 | Mar 1, 2026 (estimated) |
| NCT05283486 | Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty | Phase 2 | Completed | Feb 1, 2022 | Jun 7, 2023 (actual) |
| NCT05077865 | Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects | Phase 1 | Completed | Apr 26, 2021 | Aug 1, 2021 (actual) |
| NCT04349761 | Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects | Phase 1 | Completed | Jun 11, 2019 | Dec 30, 2019 (actual) |
Raises and investors new
- Raise Private raise (SEC Form D): $7.0M sold; issuer “TNF Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗